CAR T cell therapies tested in patients with solid cancers have not proven to be highly effective, in contrast to hematological malignancies, for which 6 CAR T cell products are FDA approved (4 targeting CD19 and 2 targeting BCMA). Here, TNFRSF17 is linked to hematologic disorder.